{
    "clinical_study": {
        "@rank": "47008", 
        "arm_group": {
            "arm_group_label": "1 dose of [14C-ETC-1002]", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This Phase 1 study will assess the mass balance recover of carbon-14 (14C) labelled ETC-1002\n      and the routes and rates of excretion of [14C]-ETC-1002"
        }, 
        "brief_title": "Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Hyperlipidemia", 
        "condition_browse": {
            "mesh_term": "Hyperlipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Male Volunteers\n\n          -  BMI 10-35 kg/m2\n\n        Exclusion Criteria:\n\n          -  Hx of CV, renal, hepatic, chronic respiratory or GI disease\n\n          -  Hx of drug or alcohol abuse\n\n          -  smoking within 12 mos of screening"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044627", 
            "org_study_id": "1002-011"
        }, 
        "intervention": {
            "arm_group_label": "1 dose of [14C-ETC-1002]", 
            "intervention_name": "[14C-ETC-1002]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom", 
                    "zip": "NG11 6Js"
                }, 
                "name": "Quotient Clinical"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label,Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002 in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Quotient Clinical, Mere Way, Ruddington Fields, Ruddington, Nottinham NG11 6JS, UK", 
            "last_name": "Stuart Mair, MBChB, DRCOG, DCPSA, MFPM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom:Radiologic Authorization Submission to Administration of Radioactive Substances Advisory Committee (ARSAC)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "using mass balance recovery", 
            "measure": "Level of [14C]-ETC-1002 in urine and feces after a single dose", 
            "safety_issue": "No", 
            "time_frame": "11 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044627"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Esperion Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Esperion Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}